Literature DB >> 21238934

Complex assemblies of factors IX and X regulate the initiation, maintenance, and shutdown of blood coagulation.

Thomas Zögg1, Hans Brandstetter.   

Abstract

Blood hemostasis is accomplished by a complex network of (anti-)coagulatory and fibrinolytic processes. These physiological processes are implemented by the assembly of multiprotein complexes involving both humoral and cellular components. Coagulation factor X, and particularly, factor IX, exemplify the dramatic enhancement that is obtained by the synergistic interaction of cell surface, inorganic and protein cofactors, protease, and substrate. With a focus on structure-function relationship, we review the current knowledge of activity modulation principles in the coagulation proteases factors IX and X and indicate future challenges for hemostasis research. This chapter is organized by describing the principles of hierarchical activation of blood coagulation proteases, including endogenous and exogenous protease activators, cofactor binding, substrate specificities, and protein inhibitors. We conclude by outlining pharmaceutical opportunities for unmet needs in hemophilia and thrombosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238934     DOI: 10.1016/B978-0-12-385504-6.00002-6

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  8 in total

1.  Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Lindsey A George; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2019-06-20

2.  Exosites expedite blood coagulation.

Authors:  Maria Luiza Vilela Oliva; Ingrid Dreveny; Jonas Emsley
Journal:  J Biol Chem       Date:  2020-11-06       Impact factor: 5.157

3.  A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection.

Authors:  Jacob E Choby; Andrew J Monteith; Lauren E Himmel; Paris Margaritis; Jana K Shirey-Rice; Andrea Pruijssers; Rebecca N Jerome; Jill Pulley; Eric P Skaar
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

4.  Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.

Authors:  Nicolas Collin; Teresa C F Assumpção; Daniella M Mizurini; Dana C Gilmore; Angélica Dutra-Oliveira; Michalis Kotsyfakis; Anderson Sá-Nunes; Clarissa Teixeira; José M C Ribeiro; Robson Q Monteiro; Jesus G Valenzuela; Ivo M B Francischetti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-12       Impact factor: 8.311

5.  Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).

Authors:  Michael Dockal; Rudolf Hartmann; Markus Fries; M Christella L G D Thomassen; Alexandra Heinzmann; Hartmut Ehrlich; Jan Rosing; Frank Osterkamp; Thomas Polakowski; Ulrich Reineke; Andreas Griessner; Hans Brandstetter; Friedrich Scheiflinger
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

6.  Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus.

Authors:  Vallerinteavide Mavelli Girish; R Manjunatha Kini
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

7.  A candidate activation pathway for coagulation factor VII.

Authors:  Tina M Misenheimer; Kraig T Kumfer; Barbara E Bates; Emily R Nettesheim; Bradford S Schwartz
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

8.  Sirtilins - the new old members of the vitamin K-dependent coagulation factor family.

Authors:  Sven O Dahms; Fatih Demir; Pitter F Huesgen; Karina Thorn; Hans Brandstetter
Journal:  J Thromb Haemost       Date:  2019-02-13       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.